



030639.0027.UTL

n re the Application of:	, 8
if the Application of.	Group Art Unit: 161
Kolterman, et al.) The state of the
00/756 600) Examiner: TBA
Serial No.: 09/756,690)
Filed: January 9, 2001)
,)
For: USE OF EXENDINS AND)
AGONISTS THEREOF FOR)
MODULATION OF TRIGLYCERIDE)
LEVELS AND TREATMENT OF)

TRANSMITTAL LETTER

Commissioner for Patents Washington, D.C. 20231

DYSLIPIDEMIA

Sir:

Enclosed are the following documents:

- Transmittal Letter;
- Information Disclosure Statement
- PTO Form 1449
- Copies of 40 cited references
- Return Postcard

CERTIFICATE OF MAILING (37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit

No fee is believed due in connection with this transmittal. However, if any fee is due, kindly charge the appropriate amount to Deposit Account No. 50-1273.

Respectfully submitted,

BROBECK, PHLEGER & HARRISON LLP

Dated:

By:

Edward O. Kreusser

Reg. No. 38,523

BROBECK, PHLEGER & HARRISON LLP 12390 El Camino Real

San Diego, CA 92130-2081

Phone (858) 720-2500

Fax (858) 720-2555





Patent 030639.0027.UTL

In re the Application of:) Group Art Unit: 1614
Kolterman, et al.) Examiner: TBA
Serial No.: 09/756,690) Examiner: IBA)
Filed: January 9, 2001)))
For: USE OF EXENDINS AND AGONISTS THEREOF FOR MODULATION OF TRIGLYCERIDE LEVELS AND TREATMENT OF DYSLIPIDEMIA))))))
INFORMATION DISCLOSURE STATEMENT	
Commissioner for Patents Washington, D.C. 20231	
Sir:	
In compliance with the Applicants' duty un	der 37 CFR 1.97-98, the following information is
brought to the attention of the Examiner. The item	s are listed on the attached Form PTO-1449 and
copies are enclosed for the convenience of the Exa	miner.
The items identified in this Information Disclosure Statement may or may not be "material"	
pursuant to 37 CFR 1.56 and the submission thereof by Applicants shall not be construed as an	
admission that any such patent, publication or other	r information referred to therein is material or
CERTIFICATE (37 C.F.F.	
I hereby certify that this paper (along with any referred to as United States Postal Service on the date shown below with su addressed to the Commissioner for Patents, Washington, D.C.	being attached or enclosed) is being deposited with the afficient postage as First Class Mail in an envelope
	Laura Jullivan
Aprile 11,200	Name of Person Mailing Paper Aug Sullyan Signature of Person Mailing Paper
Date of Deposit	egiature of reison wanning raper

considered to be material (37 CFR 1.97(h)), or even qualifies as "prior art" under 35 U.S.C. § 102 with respect to this invention unless specifically designated by Applicants as such.

The filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information, as defined in 37 CFR 1.56, exists.

This Supplemental Information Disclosure Statement is believed to be timely in that it is being submitted under 37 CFR 1.97(b) (3) before the mailing of a first Office Action on the merits, whereby no petition or fee is required. However, if counsel for Applicant is in error in this regard, the Commissioner is requested to consider this a petition and he is authorized to charge any required petition fee to counsel's Deposit Account No. 50-1273.

Respectfully submitted,

BROBECK, PHLEGER & HARRISON LLP

Dated:

Bv:

Reg. No. 38,523

BROBECK, PHLEGER & HARRISON LLP 12390 El Camino Real San Diego, CA 92130-2081

Phone

(858) 720-2500

Fax

(858) 720-2555